113 related articles for article (PubMed ID: 1707642)
1. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor.
Priel E; Showalter SD; Blair DG
AIDS Res Hum Retroviruses; 1991 Jan; 7(1):65-72. PubMed ID: 1707642
[TBL] [Abstract][Full Text] [Related]
2. Cellular topoisomerase I activity associated with HIV-1.
Jardine D; Tachedjian G; Locarnini S; Birch C
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1245-50. PubMed ID: 8142141
[TBL] [Abstract][Full Text] [Related]
3. Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.
Zhang JL; Sharma PL; Li CJ; Dezube BJ; Pardee AB; Crumpacker CS
Antimicrob Agents Chemother; 1997 May; 41(5):977-81. PubMed ID: 9145855
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I.
Takahashi H; Matsuda M; Kojima A; Sata T; Andoh T; Kurata T; Nagashima K; Hall WW
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5694-8. PubMed ID: 7539924
[TBL] [Abstract][Full Text] [Related]
5. The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.
Priel E; Showalter SD; Roberts M; Oroszlan S; Blair DG
J Virol; 1991 Aug; 65(8):4137-41. PubMed ID: 1649321
[TBL] [Abstract][Full Text] [Related]
6. Role of DNA topoisomerase I in the replication of herpes simplex virus type 2.
Yamada Y; Yamamoto N; Maeno K; Nishiyama Y
Arch Virol; 1990; 110(1-2):121-7. PubMed ID: 2155595
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase I dissociates human immunodeficiency virus type 1 reverse transcriptase from genomic RNAs.
Takahashi H; Sawa H; Hasegawa H; Nagashima K; Sata T; Kurata T
Biochem Biophys Res Commun; 2004 Jan; 313(4):1073-8. PubMed ID: 14706652
[TBL] [Abstract][Full Text] [Related]
8. The proteinase inhibitor pepstatin A inhibits formation of reverse transcriptase in H9 cells infected with human immunodeficiency virus 1.
Grinde B; Hungnes O; Tjøtta E
AIDS Res Hum Retroviruses; 1989 Jun; 5(3):269-74. PubMed ID: 2471542
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro.
Montaner LJ; Griffin P; Gordon S
J Gen Virol; 1994 Dec; 75 ( Pt 12)():3393-400. PubMed ID: 7527834
[TBL] [Abstract][Full Text] [Related]
10. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an in vivo metabolite of oltipraz.
Prochaska HJ; Bornmann WG; Baron P; Polsky B
Mol Pharmacol; 1995 Jul; 48(1):15-20. PubMed ID: 7542738
[TBL] [Abstract][Full Text] [Related]
12. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
[TBL] [Abstract][Full Text] [Related]
14. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
[TBL] [Abstract][Full Text] [Related]
15. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
Tanizawa A; Pommier Y
Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a camptothecin-resistant human DNA topoisomerase I in an in vitro system for Simian virus 40 DNA replication.
Ishimi Y; Nishizawa M; Andoh T
Eur J Biochem; 1991 Dec; 202(3):835-9. PubMed ID: 1662615
[TBL] [Abstract][Full Text] [Related]
18. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase I and ATP activate cDNA synthesis of human immunodeficiency virus type 1.
Takahashi H; Sawa H; Hasegawa H; Shoya Y; Sata T; Hall WW; Nagashima K; Kurata T
Biochem Biophys Res Commun; 2002 Jun; 294(2):509-17. PubMed ID: 12051740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
